[Current status and trends in blood biologicals]

Area of Science:

• Biotechnology and Pharmaceutical Sciences
• Hematology
• Immunology

Context:

• Blood products, including albumin, immunoglobulins, and coagulation factors, are critical therapeutics.
• These biologicals are derived from human plasma or produced via recombinant DNA technology.
• The field is rapidly evolving with new product development and therapeutic applications.

Purpose:

• To provide a comprehensive overview of plasma protein characteristics and classification.
• To review the current status and applications of key blood products.
• To discuss future trends and challenges in blood product development.

Summary:

• Human serum albumin (HSA) is a widely used therapeutic protein with ongoing advancements in its production and application.
• Immunoglobulins, including normal, IVIG, SCIG, and specific types, offer diverse treatments for immune deficiencies and infections.
• Coagulation factors and microcontent proteins are essential for treating bleeding disorders and other conditions, with recombinant alternatives emerging.

Impact:

• The development of novel recombinant plasma proteins offers alternatives to traditional plasma-derived products.
• Plasma-derived preparations maintain a unique clinical position and significant therapeutic impact.
• Continued innovation in blood product development is a key focus in global pharmaceutical research, presenting opportunities and challenges, particularly in bridging developmental gaps between nations.